Cargando…
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
OBJECTIVE: In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value. PATIENTS AND METHODS: Overall 208 patients with...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558136/ https://www.ncbi.nlm.nih.gov/pubmed/25915155 |
_version_ | 1782388584250081280 |
---|---|
author | Styczen, Hanna Nagelmeier, Iris Beissbarth, Tim Nietert, Manuel Homayounfar, Kia Sprenger, Thilo Boczek, Ute Stanek, Kathrin Kitz, Julia Wolff, Hendrik A. Ghadimi, B. Michael Middel, Peter Liersch, Torsten Rüschoff, Josef Conradi, Lena-Christin |
author_facet | Styczen, Hanna Nagelmeier, Iris Beissbarth, Tim Nietert, Manuel Homayounfar, Kia Sprenger, Thilo Boczek, Ute Stanek, Kathrin Kitz, Julia Wolff, Hendrik A. Ghadimi, B. Michael Middel, Peter Liersch, Torsten Rüschoff, Josef Conradi, Lena-Christin |
author_sort | Styczen, Hanna |
collection | PubMed |
description | OBJECTIVE: In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value. PATIENTS AND METHODS: Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months. RESULTS: Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM. High expression of HER-3 (IHC score 2+ and IHC 3+) was detected in 75.0% of liver metastases. CSS after liver surgery was determined and was independent from the HER-2 status (p = 0.963); however HER-3 was prognostic with a favorable course for patients showing an overexpression of HER-3 (p = 0.037). CONCLUSIONS: HER-2 overexpression occurs in only 8% of patients with CRLM but with 75% of cases HER-3 is frequently overexpressed in CRLM. Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches. |
format | Online Article Text |
id | pubmed-4558136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-45581362015-09-09 HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer Styczen, Hanna Nagelmeier, Iris Beissbarth, Tim Nietert, Manuel Homayounfar, Kia Sprenger, Thilo Boczek, Ute Stanek, Kathrin Kitz, Julia Wolff, Hendrik A. Ghadimi, B. Michael Middel, Peter Liersch, Torsten Rüschoff, Josef Conradi, Lena-Christin Oncotarget Research Paper OBJECTIVE: In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value. PATIENTS AND METHODS: Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months. RESULTS: Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM. High expression of HER-3 (IHC score 2+ and IHC 3+) was detected in 75.0% of liver metastases. CSS after liver surgery was determined and was independent from the HER-2 status (p = 0.963); however HER-3 was prognostic with a favorable course for patients showing an overexpression of HER-3 (p = 0.037). CONCLUSIONS: HER-2 overexpression occurs in only 8% of patients with CRLM but with 75% of cases HER-3 is frequently overexpressed in CRLM. Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches. Impact Journals LLC 2015-04-13 /pmc/articles/PMC4558136/ /pubmed/25915155 Text en Copyright: © 2015 Styczen et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Styczen, Hanna Nagelmeier, Iris Beissbarth, Tim Nietert, Manuel Homayounfar, Kia Sprenger, Thilo Boczek, Ute Stanek, Kathrin Kitz, Julia Wolff, Hendrik A. Ghadimi, B. Michael Middel, Peter Liersch, Torsten Rüschoff, Josef Conradi, Lena-Christin HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer |
title | HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer |
title_full | HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer |
title_fullStr | HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer |
title_full_unstemmed | HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer |
title_short | HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer |
title_sort | her-2 and her-3 expression in liver metastases of patients with colorectal cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558136/ https://www.ncbi.nlm.nih.gov/pubmed/25915155 |
work_keys_str_mv | AT styczenhanna her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT nagelmeieriris her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT beissbarthtim her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT nietertmanuel her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT homayounfarkia her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT sprengerthilo her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT boczekute her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT stanekkathrin her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT kitzjulia her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT wolffhendrika her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT ghadimibmichael her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT middelpeter her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT lierschtorsten her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT ruschoffjosef her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer AT conradilenachristin her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer |